- Adults living with lymphoblastic leukaemia in deprived areas of England have 15-20 per cent higher risk of dying.
- Study also found patients treated at hospitals which manage small number of leukaemia cases also have significantly lower survival rate.
- Findings could have implications for how NHS treat leukaemia patients, with an argument for specialist centres.
Adults with acute lymphoblastic leukaemia living in deprived areas of England have poorer survival rates, a new study has found.
The research, conducted by experts from the University of Sheffield, also found adult patients treated at hospitals which manage small numbers of leukaemia cases also have a significantly lower survival rate.
Acute lymphoblastic leukaemia is a type of blood cancer that starts from young white blood cells called lymphocytes in the bone marrow - the soft inner part of the bones where new blood cells are made. The condition is rare, especially in adults.
The findings, published in the journal BMC Cancer, show adult patients with the condition living in more socioeconomically deprived areas had around 15-20 per cent higher mortality than patients living in the least deprived areas.
Meanwhile, patients treated at hospitals which manage small numbers of patients with this rare condition had around 30 per cent higher mortality compared to hospitals treating larger numbers of adult patients with the condition.
Professor Ravi Maheswaran and his team from the University of Sheffield's School of Health and Related Research (ScHARR) analysed anonymised NHS data on hospital admissions.
They found 2,921 adults aged over 18 years were diagnosed with this type of leukaemia from 2001-12. They also assessed follow-up data on survival rates up to 2013.
Their results indicate that around 1 in 160,000 adults in England will develop this type of leukaemia each year.
Estimated five-year survival for all adults, which included elderly patients with the condition, was not good with only around a third of all patients predicted to survive five years after diagnosis. The results did however show that survival had improved over the time period examined.
Professor Maheswaran from ScHARR, said: "The findings are likely to have significant implications for the organisation of NHS services for the treatment of adults with this rare but serious condition.
"These results, although concerning, are from a single study and further work is needed to confirm our findings.
"If the association between high deprivation and poorer survival is confirmed, more investigation will be needed to understand why adults with this type of leukaemia living in deprived areas have poorer survival and what can be done to address this inequality.
He added: "Confirmation that hospitals treating few patients with this rare condition have worse outcomes would mean that the NHS should seriously consider if treatment services for adults with acute lymphoblastic leukaemia should mainly be provided by specialist centres in order to improve survival."
###
ScHARR at the University of Sheffield tackles some of the world's biggest health challenges. To find out more please visit https://www.sheffield.ac.uk/scharr .
For further information please contact: Amy Huxtable, Media Relations Officer, University of Sheffield, 0114-222-9859
Notes to editors
The University of Sheffield
With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world's leading universities.
A member of the UK's prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.
Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.
Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2017 and was voted number one university in the UK for Student Satisfaction by Times Higher Education in 2014. In the last decade it has won four Queen's Anniversary Prizes in recognition of the outstanding contribution to the United Kingdom's intellectual, economic, cultural and social life.
Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.
Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.
To read other news releases about the University of Sheffield, visit http://www.shef.ac.uk/news
Journal
BMC Cancer